{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T07:06:45Z","timestamp":1791184005347,"version":"4.1.0"},"reference-count":113,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2014,6,13]],"date-time":"2014-06-13T00:00:00Z","timestamp":1402617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2014,6,13]],"date-time":"2014-06-13T00:00:00Z","timestamp":1402617600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Immunol"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1038\/nri3694","type":"journal-article","created":{"date-parts":[[2014,6,13]],"date-time":"2014-06-13T06:40:57Z","timestamp":1402641657000},"page":"505-514","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":199,"title":["From empiricism to rational design: a personal perspective of the evolution of vaccine development"],"prefix":"10.1038","volume":"14","author":[{"given":"Ennio","family":"De Gregorio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rino","family":"Rappuoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,6,13]]},"reference":[{"key":"BFnri3694_CR1","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1056\/NEJMms1215400","volume":"369","author":"WG van Panhuis","year":"2013","unstructured":"van Panhuis, W. G. et al. Contagious diseases in the United States from 1888 to the present. N. Engl. J. Med. 369, 2152\u20132158 (2013).","journal-title":"N. Engl. J. Med."},{"key":"BFnri3694_CR2","unstructured":"World Health Organization. Global Vaccine Action Plan 2011-2020. (WHO, 2013)."},{"key":"BFnri3694_CR3","doi-asserted-by":"crossref","unstructured":"Thucydides. The History of the Peloponnesian War (University of Chicago Press, 1989).","DOI":"10.7208\/chicago\/9780226801056.001.0001"},{"key":"BFnri3694_CR4","first-page":"6","volume":"19","author":"J Needham","year":"1980","unstructured":"Needham, J. China and the origins of immunology. East Horiz. 19, 6\u201312 (1980).","journal-title":"East Horiz."},{"key":"BFnri3694_CR5","first-page":"65","volume-title":"Vaccinia, Vaccination, Vaccinoiogy: Jenner, Pasteur and Their Successors","author":"AK Leung","year":"1996","unstructured":"Leung, A. K. in Vaccinia, Vaccination, Vaccinoiogy: Jenner, Pasteur and Their Successors (eds Plotkin, S. A. & Fantini, B.) 65\u201371 (Elsevier, 1996)."},{"key":"BFnri3694_CR6","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1002\/rmv.443","volume":"14","author":"S Blower","year":"2004","unstructured":"Blower, S. & Bernoulli, D. An attempt at a new analysis of the mortality caused by smallpox and of the advantages of inoculation to prevent it. Rev. Med. Virol. 14, 275\u2013288 (2004).","journal-title":"Rev. Med. Virol."},{"key":"BFnri3694_CR7","first-page":"1032","volume-title":"Fundamental Immunology","author":"E De Gregorio","year":"2013","unstructured":"De Gregorio, E. et al. in Fundamental Immunology (ed. Paul W. E.) 1032\u20131068 (Lippicott Williams & Wilkins, 2013)."},{"key":"BFnri3694_CR8","volume-title":"An Inquiry into the Causes and Effects ofthe Variolae Vaccinae","author":"E Jenner","year":"1798","unstructured":"Jenner, E. An Inquiry into the Causes and Effects ofthe Variolae Vaccinae (Sampson Low, 1798)."},{"key":"BFnri3694_CR9","doi-asserted-by":"publisher","first-page":"264","DOI":"10.3855\/jidc.1204","volume":"4","author":"E Tognotti","year":"2010","unstructured":"Tognotti, E. The eradication of smallpox, a success story for modern medicine and public health: what lessons for the future? J. Infect. Dev. Ctries 4, 264\u2013266 (2010).","journal-title":"J. Infect. Dev. Ctries"},{"key":"BFnri3694_CR10","first-page":"673","volume":"91","author":"L Pasteur","year":"1880","unstructured":"Pasteur, L. De l'attenuation du virus du cholera des poules. C. R. Acad. Sci. Paris 91, 673\u2013680 (in French) (1880).","journal-title":"C. R. Acad. Sci. Paris"},{"key":"BFnri3694_CR11","first-page":"765","volume":"101","author":"L Pasteur","year":"1885","unstructured":"Pasteur, L. M\u00e9thode pour pr\u00e9venir la rage apr\u00e8s morsure. C. R. Acad. Sci. Paris 101, 765\u2013772 (in French) (1885).","journal-title":"C. R. Acad. Sci. Paris"},{"key":"BFnri3694_CR12","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1055\/s-0029-1207589","volume":"16","author":"E von Behring","year":"1890","unstructured":"von Behring, E. et al. Uber das zustandekommen der diphtherie-immunitat und der tetanus-immunitat bie tieren. Dtsch Med. Wochenschr. 16, 1113\u20131114 (in German) (1890).","journal-title":"Dtsch Med. Wochenschr."},{"key":"BFnri3694_CR13","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1055\/s-0029-1207609","volume":"16","author":"E Von Behring","year":"1890","unstructured":"Von Behring, E. Untersuchungen iiber das zustandekommen der diphterie-immunitat bei tieren. Dtsch Med. Wochenschr. 16, 1145\u20131148 (in German) (1890).","journal-title":"Dtsch Med. Wochenschr."},{"key":"BFnri3694_CR14","first-page":"329","volume":"28","author":"A Calmette","year":"1914","unstructured":"Calmette, A. & Gu\u00e9rin, C. Contribution \u00e0 l'\u00e9tude de l'immunit\u00e9 antituberculose chez les bovid\u00e9s. Ann. Inst. Pasteur 28, 329\u2013337 (in French) (1914).","journal-title":"Ann. Inst. Pasteur"},{"key":"BFnri3694_CR15","first-page":"283","volume":"4","author":"AT Glenny","year":"1923","unstructured":"Glenny, A. T. & Hopkins, B. E. Diphtheria toxoid as an immunising agent. Br. J. Exp. Pathol. 4, 283\u2013288 (1923).","journal-title":"Br. J. Exp. Pathol."},{"key":"BFnri3694_CR16","first-page":"1338","volume":"177","author":"G Ramon","year":"1923","unstructured":"Ramon, G. Sur le pouvoir floculant et sur les propri\u00e9t\u00e9s immunisationes d'une toxine dipht\u00e9rique rendue anatoxique (anatoxine). C R. Acad. Sci. Paris 177, 1338\u20131340 (in French) (1923).","journal-title":"C R. Acad. Sci. Paris"},{"key":"BFnri3694_CR17","doi-asserted-by":"publisher","first-page":"563","DOI":"10.2105\/AJPH.44.5.563","volume":"44","author":"JE Salk","year":"1954","unstructured":"Salk, J. E. et al. Formaldehyde treatment and safety testing of experimental poliomyelitis vaccines. Am. J. Publ. Health Nat. Health 44, 563\u2013570 (1954).","journal-title":"Am. J. Publ. Health Nat. Health"},{"key":"BFnri3694_CR18","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1084\/jem.99.6.551","volume":"99","author":"AB Sabin","year":"1954","unstructured":"Sabin, A. B., Hennessen, W. A. & Winsser, J. Studies on variants of poliomyelitis virus. I. Experimental segregation and properties of avirulent variants of three immunologic types. J. Exp. Med. 99, 551\u2013576 (1954).","journal-title":"J. Exp. Med."},{"key":"BFnri3694_CR19","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1056\/NEJM196007282630408","volume":"263","author":"SL Katz","year":"1960","unstructured":"Katz, S. L. et al. Studies on an attenuated measles-virus vaccine. VIII. General summary and evaluation of the results of vaccine. N. Engl. J. Med. 263, 180\u2013184 (1960).","journal-title":"N. Engl. J. Med."},{"key":"BFnri3694_CR20","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1001\/jama.1968.03150030043009","volume":"206","author":"MR Hilleman","year":"1968","unstructured":"Hilleman, M. R. et al. Development and evaluation of the Moraten measles virus vaccine. JAMA 206, 587\u2013590 (1968).","journal-title":"JAMA"},{"key":"BFnri3694_CR21","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1056\/NEJM196802012780501","volume":"278","author":"MR Hilleman","year":"1968","unstructured":"Hilleman, M. R., Buynak, E. B., Weibel, R. E. & Stokes, J. Jr. Live, attenuated mumps-virus vaccine. N. Engl. J. Med. 278, 227\u2013232 (1968).","journal-title":"N. Engl. J. Med."},{"key":"BFnri3694_CR22","first-page":"178","volume":"118","author":"SA Plotkin","year":"1969","unstructured":"Plotkin, S. A., Farquhar, J. D., Katz, M. & Buser, F. Attenuation of RA 27\u201323 rubella virus in WI-38 human diploid cells. Am. J. Dis. Child 118, 178\u2013185 (1969).","journal-title":"Am. J. Dis. Child"},{"key":"BFnri3694_CR23","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1056\/NEJM198405313102201","volume":"310","author":"RE Weibel","year":"1984","unstructured":"Weibel, R. E. et al. Live attenuated varicella virus vaccine. Efficacy trial in healthy children. N. Engl. J. Med. 310, 1409\u20131415 (1984).","journal-title":"N. Engl. J. Med."},{"key":"BFnri3694_CR24","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1097\/01.inf.0000220232.44916.a8","volume":"25","author":"SA Plotkin","year":"2006","unstructured":"Plotkin, S. A. New rotavirus vaccines. Pediatr. Infect. Dis. J. 25, 575\u2013576 (2006).","journal-title":"Pediatr. Infect. Dis. J."},{"key":"BFnri3694_CR25","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1542\/peds.56.6.991","volume":"56","author":"CB Hall","year":"1975","unstructured":"Hall, C. B., Douglas, G. Jr & Fralonardo, S. A. Live attenuated influenza virus vaccine trial in children. Pediatrics 56, 991\u2013998 (1975).","journal-title":"Pediatrics"},{"key":"BFnri3694_CR26","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1084\/jem.129.6.1307","volume":"129","author":"I Goldschneider","year":"1969","unstructured":"Goldschneider, I., Gotschlich, E. C. & Artenstein, M. S. Human immunity to the meningococcus. I. The role of humoral antibodies. J. Exp. Med. 129, 1307\u20131326 (1969).","journal-title":"J. Exp. Med."},{"key":"BFnri3694_CR27","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1084\/jem.129.6.1349","volume":"129","author":"EC Gotschlich","year":"1969","unstructured":"Gotschlich, E. C., Liu, T. Y. & Artenstein, M. S. Human immunity to the meningococcus. 3. Preparation and immunochemical properties of the group A, group B, and group C meningococcal polysaccharides. J. Exp. Med. 129, 1349\u20131365 (1969).","journal-title":"J. Exp. Med."},{"key":"BFnri3694_CR28","first-page":"127","volume-title":"Vaccinia, Vaccination, Vaccinology: Jenner, Pasteur, and Their Successors","author":"R Austrian","year":"1996","unstructured":"Austrian, R. in Vaccinia, Vaccination, Vaccinology: Jenner, Pasteur, and Their Successors. (eds Plotkin, S. A. & Fantini, B.) 127\u2013133 (Elsevier, 1996)."},{"key":"BFnri3694_CR29","first-page":"184","volume":"89","author":"R Austrian","year":"1976","unstructured":"Austrian, R. et al. Prevention of pneumococcal pneumonia by vaccination. Trans. Assoc. Am. Physicians 89, 184\u2013194 (1976).","journal-title":"Trans. Assoc. Am. Physicians"},{"key":"BFnri3694_CR30","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1172\/JCI106794","volume":"51","author":"P Anderson","year":"1972","unstructured":"Anderson, P. et al. Immunization of humans with polyribophosphate, the capsular antigen of Hemophilus influenzae, type b. J. Clin. Invest. 51, 39\u201344 (1972).","journal-title":"J. Clin. Invest."},{"key":"BFnri3694_CR31","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1084\/jem.50.4.533","volume":"50","author":"OT Avery","year":"1929","unstructured":"Avery, O. T. & Goebel, W. F. Chemo-immunological studies on conjugated carbohydrate-proteins: II. immunological specificity of synthetic sugar-protein antigens. J. Exp. Med. 50, 533\u2013550 (1929).","journal-title":"J. Exp. Med."},{"key":"BFnri3694_CR32","first-page":"77","volume":"47","author":"R Schneerson","year":"1980","unstructured":"Schneerson, R. et al. Haemophilus influenzae type B polysaccharide-protein conjugates: model for a new generation of capsular polysaccharide vaccines. Prog. Clin. Biol. Res. 47, 77\u201394 (1980).","journal-title":"Prog. Clin. Biol. Res."},{"key":"BFnri3694_CR33","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/0264-410X(92)90091-W","volume":"10","author":"P Costantino","year":"1992","unstructured":"Costantino, P. et al. Development and phase 1 clinical testing of a conjugate vaccine against meningococcus A and C. Vaccine 10, 691\u2013698 (1992).","journal-title":"Vaccine"},{"key":"BFnri3694_CR34","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1136\/adc.85.5.391","volume":"85","author":"R Lakshman","year":"2001","unstructured":"Lakshman, R. et al. Safety of a new conjugate meningococcal C vaccine in infants. Arch. Dis. Child 85, 391\u2013397 (2001).","journal-title":"Arch. Dis. Child"},{"key":"BFnri3694_CR35","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1097\/00006454-200003000-00003","volume":"19","author":"S Black","year":"2000","unstructured":"Black, S. et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr. Infect. Dis. J. 19, 187\u2013195 (2000).","journal-title":"Pediatr. Infect. Dis. J."},{"key":"BFnri3694_CR36","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1517\/14712598.5.11.1475","volume":"5","author":"ME Pichichero","year":"2005","unstructured":"Pichichero, M. E. Meningococcal conjugate vaccines. Expert Opin. Biol. Ther. 5, 1475\u20131489 (2005).","journal-title":"Expert Opin. Biol. Ther."},{"key":"BFnri3694_CR37","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/j.vaccine.2013.12.034","volume":"32","author":"A Abdelnour","year":"2014","unstructured":"Abdelnour, A. et al. Safety of a quadrivalent meningococcal serogroups A, C, W and Y conjugate vaccine (MenACWY-CRM) administered with routine infant vaccinations: results of an open-label, randomized, phase 3b controlled study in healthy infants. Vaccine 32, 965\u2013972 (2014).","journal-title":"Vaccine"},{"key":"BFnri3694_CR38","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s40272-013-0047-z","volume":"15","author":"GL Plosker","year":"2013","unstructured":"Plosker, G. L. 13-valent pneumococcal conjugate vaccine: a review of its use in infants, children, and adolescents. Paediatr. Drugs 15, 403\u2013423 (2013).","journal-title":"Paediatr. Drugs"},{"issue":"Suppl. 4","key":"BFnri3694_CR39","doi-asserted-by":"publisher","first-page":"D52","DOI":"10.1016\/j.vaccine.2013.02.029","volume":"31","author":"SA Madhi","year":"2013","unstructured":"Madhi, S. A. et al. Considerations for a phase-III trial to evaluate a group B Streptococcus polysaccharide-protein conjugate vaccine in pregnant women for the prevention of early- and late-onset invasive disease in young-infants. Vaccine 31 (Suppl. 4), D52\u2013D57 (2013).","journal-title":"Vaccine"},{"key":"BFnri3694_CR40","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1056\/NEJM200104263441701","volume":"344","author":"FY Lin","year":"2001","unstructured":"Lin, F. Y. et al. The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children. N. Engl. J. Med. 344, 1263\u20131269 (2001).","journal-title":"N. Engl. J. Med."},{"key":"BFnri3694_CR41","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S1473-3099(13)70241-X","volume":"14","author":"ZA Bhutta","year":"2013","unstructured":"Bhutta, Z. A. et al. Immunogenicity and safety of the Vi-CRM197 conjugate vaccine against typhoid fever in adults, children, and infants in south and southeast Asia: results from two randomised, observer-blind, age de-escalation, phase 2 trials. Lancet Infect. Dis. 14, 119\u2013129 (2013).","journal-title":"Lancet Infect. Dis."},{"key":"BFnri3694_CR42","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1038\/nm.2587","volume":"17","author":"R Rappuoli","year":"2011","unstructured":"Rappuoli, R. & De Gregorio, E. A sweet T cell response. Nature Med. 17, 1551\u20131552 (2011).","journal-title":"Nature Med."},{"key":"BFnri3694_CR43","doi-asserted-by":"publisher","first-page":"694","DOI":"10.3181\/00379727-151-39288","volume":"151","author":"EB Buynak","year":"1976","unstructured":"Buynak, E. B. et al. Development and chimpanzee testing of a vaccine against human hepatitis B. Proc. Soc. Exp. Biol. Med. 151, 694\u2013700 (1976).","journal-title":"Proc. Soc. Exp. Biol. Med."},{"key":"BFnri3694_CR44","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/298347a0","volume":"298","author":"P Valenzuela","year":"1982","unstructured":"Valenzuela, P., Medina, A., Rutter, W. J., Ammerer, G. & Hall, B. D. Synthesis and assembly of hepatitis B virus surface antigen particles in yeast. Nature 298, 347\u2013350 (1982).","journal-title":"Nature"},{"key":"BFnri3694_CR45","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1017\/S0950268800054625","volume":"104","author":"E Dahl-Hansen","year":"1990","unstructured":"Dahl-Hansen, E., Siebke, J. C., Froland, S. S. & Degr\u00e9, M. Immunogenicity of yeast-derived hepatitis B vaccine from two different producers. Epidemiol. Infect. 104, 143\u2013149 (1990).","journal-title":"Epidemiol. Infect."},{"key":"BFnri3694_CR46","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/0042-6822(91)90772-4","volume":"185","author":"J Zhou","year":"1991","unstructured":"Zhou, J., Sun, X. Y., Stenzel, D. J. & Frazer, I. H. Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology 185, 251\u2013257 (1991).","journal-title":"Virology"},{"key":"BFnri3694_CR47","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1002\/bit.25159","volume":"111","author":"LH Lua","year":"2014","unstructured":"Lua, L. H. et al. Bioengineering virus-like particles as vaccines. Biotechnol. Bioeng. 111, 425\u2013440 (2014).","journal-title":"Biotechnol. Bioeng."},{"key":"BFnri3694_CR48","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/0304-4165(76)90323-8","volume":"444","author":"H Arai","year":"1976","unstructured":"Arai, H. & Sato, Y. Separation and characterization of two distinct hemagglutinins contained in purified leukocytosis-promoting factor from Bordetella pertussis. Biochim. Biophys. Acta 444, 765\u2013782 (1976).","journal-title":"Biochim. Biophys. Acta"},{"key":"BFnri3694_CR49","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/S0140-6736(84)90061-8","volume":"1","author":"Y Sato","year":"1984","unstructured":"Sato, Y., Kimura, M. & Fukumi, H. Development of a pertussis component vaccine in Japan. Lancet 1, 122\u2013126 (1984).","journal-title":"Lancet"},{"issue":"Suppl. 4","key":"BFnri3694_CR50","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1097\/00006454-199704001-00002","volume":"16","author":"EL Hewlett","year":"1997","unstructured":"Hewlett, E. L. Pertussis: current concepts of pathogenesis and prevention. Pediatr. Infect. Dis. J. 16 (Suppl. 4), 78\u201384 (1997).","journal-title":"Pediatr. Infect. Dis. J."},{"key":"BFnri3694_CR51","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1126\/science.2683073","volume":"246","author":"M Pizza","year":"1989","unstructured":"Pizza, M. et al. Mutants of pertussis toxin suitable for vaccine development. Science 246, 497\u2013500 (1989).","journal-title":"Science"},{"key":"BFnri3694_CR52","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1038\/nm0497-374","volume":"3","author":"R Rappuoli","year":"1997","unstructured":"Rappuoli, R. Rational design of vaccines. Nature Med. 3, 374\u2013376 (1997).","journal-title":"Nature Med."},{"key":"BFnri3694_CR53","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1056\/NEJM199602083340601","volume":"334","author":"D Greco","year":"1996","unstructured":"Greco, D. et al. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group. N. Engl. J. Med. 334, 341\u2013348 (1996).","journal-title":"N. Engl. J. Med."},{"key":"BFnri3694_CR54","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/0882-4010(89)90087-9","volume":"6","author":"FE Ashton","year":"1989","unstructured":"Ashton, F. E., Ryan, J. A., Michon, F. & Jennings, H. J. Protective efficacy of mouse serum to the N-propionyl derivative of meningococcal group B polysaccharide. Microb. Pathog. 6, 455\u2013458 (1989).","journal-title":"Microb. Pathog."},{"key":"BFnri3694_CR55","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1099\/00222615-44-4-237","volume":"44","author":"DA Ala'Aldeen","year":"1996","unstructured":"Ala'Aldeen, D. A. Transferrin receptors of Neisseria meningitidis promising candidates for a broadly cross-protective vaccine. J. Med. Microbiol. 44, 237\u2013243 (1996).","journal-title":"J. Med. Microbiol."},{"key":"BFnri3694_CR56","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0168-1656(00)00294-7","volume":"83","author":"D Martin","year":"2000","unstructured":"Martin, D. et al. Candidate Neisseria meningitidis NspA vaccine. J. Biotechnol. 83, 27\u201331 (2000).","journal-title":"J. Biotechnol."},{"key":"BFnri3694_CR57","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.4161\/hv.24129","volume":"9","author":"J Holst","year":"2013","unstructured":"Holst, J. et al. Vaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV): lessons from past programs and implications for the future. Hum. Vaccin. Immunother. 9, 1241\u20131253 (2013).","journal-title":"Hum. Vaccin. Immunother."},{"key":"BFnri3694_CR58","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1128\/JCM.38.9.3323-3328.2000","volume":"38","author":"ML Tondella","year":"2000","unstructured":"Tondella, M. L. et al. Distribution of Neisseria meningitidis serogroup B serosubtypes and serotypes circulating in the United States. The Active Bacterial Core Surveillance Team. J. Clin. Microbiol. 38, 3323\u20133328 (2000).","journal-title":"J. Clin. Microbiol."},{"key":"BFnri3694_CR59","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1126\/science.7542800","volume":"269","author":"RD Fleischmann","year":"1995","unstructured":"Fleischmann, R. D. et al. Whole-genome random sequencing and assembly of Haemophilus influenzae Rd. Science 269, 496\u2013512 (1995).","journal-title":"Science"},{"key":"BFnri3694_CR60","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1126\/science.287.5459.1809","volume":"287","author":"H Tettelin","year":"2000","unstructured":"Tettelin, H. et al. Complete genome sequence of Neisseria meningitidis serogroup B strain MC58. Science 287, 1809\u20131815 (2000).","journal-title":"Science"},{"key":"BFnri3694_CR61","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1126\/science.287.5459.1816","volume":"287","author":"M Pizza","year":"2000","unstructured":"Pizza, M. et al. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science 287, 1816\u20131820 (2000).","journal-title":"Science"},{"key":"BFnri3694_CR62","unstructured":"Princeton University. Emergency guidelines for the campus community: meningitis information. [online], (2014)."},{"key":"BFnri3694_CR63","volume-title":"Los Angeles Times","author":"C Rivera","year":"2014","unstructured":"Rivera, C. UC Santa Barbara to offer meningitis vaccine to students. Los Angeles Times [online], (2014)."},{"key":"BFnri3694_CR64","doi-asserted-by":"publisher","first-page":"6573","DOI":"10.1073\/pnas.092569199","volume":"99","author":"H Etz","year":"2002","unstructured":"Etz, H. et al. Identification of in vivo expressed vaccine candidate antigens from Staphylococcus aureus. Proc. Natl Acad. Sci. USA 99, 6573\u20136578 (2002).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnri3694_CR65","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1126\/science.1109869","volume":"309","author":"D Maione","year":"2005","unstructured":"Maione, D. et al. Identification of a universal group B streptococcus vaccine by multiple genome screen. Science 309, 148\u2013150 (2005).","journal-title":"Science"},{"key":"BFnri3694_CR66","doi-asserted-by":"publisher","first-page":"9072","DOI":"10.1073\/pnas.0915077107","volume":"107","author":"D Moriel","year":"2010","unstructured":"Moriel, D. et al. Identification of protective and broadly conserved vaccine antigens from the genome of extraintestinal pathogenic Escherichia coli. Proc. Natl Acad. Sci. USA 107, 9072\u20139077 (2010).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnri3694_CR67","doi-asserted-by":"publisher","first-page":"5028","DOI":"10.1016\/j.vaccine.2005.04.048","volume":"23","author":"S Capo","year":"2007","unstructured":"Capo, S. et al. Chlamydia pneumoniae genome sequence analysis and identification of HLA-A2-restricted CD8+ T cell epitopes recognized by infection-primed T cells. Vaccine 23, 5028\u20135037 (2007).","journal-title":"Vaccine"},{"key":"BFnri3694_CR68","doi-asserted-by":"publisher","first-page":"7948","DOI":"10.4049\/jimmunol.181.11.7948","volume":"181","author":"S Bertholet","year":"2008","unstructured":"Bertholet, S. et al. Identification of human T cell antigens for the development of vaccines against Mycobacterium tuberculosis. J. Immunol. 181, 7948\u20137957 (2008).","journal-title":"J. Immunol."},{"key":"BFnri3694_CR69","doi-asserted-by":"publisher","first-page":"4135","DOI":"10.1016\/S0264-410X(01)00173-6","volume":"19","author":"BC Ross","year":"2001","unstructured":"Ross, B. C. et al. Identification of vaccine candidate antigens from a genomic analysis of Porphyromonas gingivalis. Vaccine 19, 4135\u20134142 (2001).","journal-title":"Vaccine"},{"key":"BFnri3694_CR70","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1084\/jem.20071168","volume":"205","author":"C Giefing","year":"2007","unstructured":"Giefing, C. et al. Discovery of a novel class of highly conserved vaccine antigens using genomic scale antigenic fingerprinting of pneumococcus with human antibodies. J. Exp. Med. 205, 117\u2013131 (2007).","journal-title":"J. Exp. Med."},{"key":"BFnri3694_CR71","doi-asserted-by":"publisher","first-page":"M111.015693","DOI":"10.1074\/mcp.M111.015693","volume":"11","author":"G Bensi","year":"2012","unstructured":"Bensi, G. et al. Multi high-throughput approach for highly selective identification of vaccine candidates: the group A streptococcus case. Mol. Cell. Proteomics 11, M111.015693 (2012).","journal-title":"Mol. Cell. Proteomics"},{"key":"BFnri3694_CR72","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/S1369-5274(00)00119-3","volume":"3","author":"R Rappuoli","year":"2000","unstructured":"Rappuoli, R. Reverse vaccinology. Curr. Opin. Microbiol. 3, 445\u2013450 (2000).","journal-title":"Curr. Opin. Microbiol."},{"key":"BFnri3694_CR73","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.immuni.2010.09.017","volume":"33","author":"A Sette","year":"2010","unstructured":"Sette, A. & Rappuoli, R. Reverse vaccinology: developing vaccines in the era of genomics. Immunity 33, 530\u2013541 (2010).","journal-title":"Immunity"},{"key":"BFnri3694_CR74","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.tibtech.2008.08.002","volume":"26","author":"PR Dormitzer","year":"2008","unstructured":"Dormitzer, P. R., Ulmer, J. B. & Rappuoli, R. Structure-based antigen design: a strategy for next generation vaccines. Trends Biotechnol. 26, 659\u2013667 (2008).","journal-title":"Trends Biotechnol."},{"key":"BFnri3694_CR75","doi-asserted-by":"publisher","first-page":"91ra62","DOI":"10.1126\/scitranslmed.3002234","volume":"3","author":"M Scarselli","year":"2011","unstructured":"Scarselli, M. et al. Rational design of a meningococcal antigen inducing broad protective immunity. Sci. Transl. Med. 3, 91ra62 (2011).","journal-title":"Sci. Transl. Med."},{"key":"BFnri3694_CR76","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1126\/science.1243283","volume":"342","author":"JS McLellan","year":"2013","unstructured":"McLellan, J. S. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science 342, 592\u2013598 (2013).","journal-title":"Science"},{"key":"BFnri3694_CR77","doi-asserted-by":"crossref","unstructured":"In vaccine design, looks do matter [News]. Science 342, 1442\u20131443 (2013).","DOI":"10.1126\/science.342.6165.1442-a"},{"key":"BFnri3694_CR78","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1126\/science.1190719","volume":"329","author":"DG Gibson","year":"2010","unstructured":"Gibson, D. G. et al. Creation of a bacterial cell controlled by a chemically synthesized genome. Science 329, 52\u201356 (2010).","journal-title":"Science"},{"key":"BFnri3694_CR79","doi-asserted-by":"publisher","first-page":"185ra68","DOI":"10.1126\/scitranslmed.3006368","volume":"5","author":"PR Dormitzer","year":"2013","unstructured":"Dormitzer, P. R. et al. Synthetic generation of influenza vaccine viruses for rapid responses to pandemics. Sci. Transl. Med. 5, 185ra68 (2013).","journal-title":"Sci. Transl. Med."},{"key":"BFnri3694_CR80","doi-asserted-by":"publisher","first-page":"234ra55","DOI":"10.1126\/scitranslmed.3008761","volume":"6","author":"SA Bart","year":"2014","unstructured":"Bart, S. A. A cell culture-derived MF59-adjuvanted pandemic A\/H7N9 vaccine is immunogenic in adults. Sci. Transl. Med. 6, 234ra55 (2014).","journal-title":"Sci. Transl. Med."},{"key":"BFnri3694_CR81","doi-asserted-by":"publisher","first-page":"14604","DOI":"10.1073\/pnas.1209367109","volume":"109","author":"AJ Geall","year":"2012","unstructured":"Geall, A. J. et al. Nonviral delivery of self-amplifying RNA vaccines. Proc. Natl Acad. Sci. USA 109, 14604\u201314609 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnri3694_CR82","doi-asserted-by":"publisher","first-page":"e52","DOI":"10.1038\/emi.2013.54","volume":"2","author":"A Hekele","year":"2013","unstructured":"Hekele, A. Rapidly produced SAM\u00ae vaccine against H7N9 influenza is immunogenic in mice. Emerg. Microbes Infect. 2, e52 (2013).","journal-title":"Emerg. Microbes Infect."},{"key":"BFnri3694_CR83","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.coi.2010.04.004","volume":"22","author":"ML Mbow","year":"2010","unstructured":"Mbow, M. L., De Gregorio, E., Valiante, N. M. & Rappuoli, R. New adjuvants for human vaccines. Curr. Opin. Immunol. 22, 411\u2013416 (2010).","journal-title":"Curr. Opin. Immunol."},{"key":"BFnri3694_CR84","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1056\/NEJMoa1010331","volume":"365","author":"T Vesikari","year":"2011","unstructured":"Vesikari, T. et al. Oil-in-water emulsion adjuvant with influenza vaccine in young children. N. Engl. J. Med. 365, 1406\u20131416 (2011).","journal-title":"N. Engl. J. Med."},{"key":"BFnri3694_CR85","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1586\/erv.11.192","volume":"11","author":"N Gar\u00e7on","year":"2012","unstructured":"Gar\u00e7on, N., Vaughan, D. W. & Didierlaurent, A. M. Development and evaluation of AS03, an adjuvant system containing \u03b1-tocopherol and squalene in an oil-in-water emulsion. Expert Rev. Vaccines 11, 349\u2013366 (2012).","journal-title":"Expert Rev. Vaccines"},{"key":"BFnri3694_CR86","doi-asserted-by":"publisher","first-page":"17585","DOI":"10.1073\/pnas.1207308109","volume":"109","author":"CH Clegg","year":"2012","unstructured":"Clegg, C. H. et al. Adjuvant solution for pandemic influenza vaccine. Proc. Natl Acad. Sci. USA 109, 17585\u201317590 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnri3694_CR87","doi-asserted-by":"publisher","first-page":"217","DOI":"10.2165\/11591760-000000000-00000","volume":"25","author":"N Gar\u00e7on","year":"2011","unstructured":"Gar\u00e7on, N. et al. Development AS04-adjuvanted HPV vaccine with the adjuvant system approach. BioDrugs 25, 217\u2013226 (2011).","journal-title":"BioDrugs"},{"key":"BFnri3694_CR88","doi-asserted-by":"crossref","unstructured":"RTS,S Clinical Trials Partnership. A phase 3 trial of RTS,S\/AS01 malaria vaccine in African infants. N. Engl. J. Med. 367, 2284\u20132295 (2012).","DOI":"10.1056\/NEJMoa1208394"},{"key":"BFnri3694_CR89","doi-asserted-by":"publisher","first-page":"5306","DOI":"10.1016\/j.vaccine.2013.05.067","volume":"31","author":"RS Janssen","year":"2013","unstructured":"Janssen, R. S. et al. Immunogenicity and safety of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in patients with chronic kidney disease. Vaccine 31, 5306\u20135313 (2013).","journal-title":"Vaccine"},{"key":"BFnri3694_CR90","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1586\/erv.13.27","volume":"12","author":"A Michael","year":"2013","unstructured":"Michael, A., Relph, K., Annels, N. & Pandha, H. Prostate cancer vaccines. Expert Rev. Vaccines 12, 253\u2013262 (2013).","journal-title":"Expert Rev. Vaccines"},{"key":"BFnri3694_CR91","doi-asserted-by":"publisher","first-page":"158","DOI":"10.3389\/fonc.2012.00158","volume":"2","author":"MZ Ladjemi","year":"2012","unstructured":"Ladjemi, M. Z. Anti-idiotypic antibodies as cancer vaccines: achievements and future improvements. Front. Oncol. 2, 158 (2012).","journal-title":"Front. Oncol."},{"key":"BFnri3694_CR92","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1126\/science.8456302","volume":"259","author":"JB Ulmer","year":"1993","unstructured":"Ulmer, J. B. et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 259, 1745\u20131749 (1993).","journal-title":"Science"},{"key":"BFnri3694_CR93","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1093\/infdis\/jiq114","volume":"203","author":"DW Fitzgerald","year":"2011","unstructured":"Fitzgerald, D. W. et al. An Ad5-vectored HIV-1 vaccine elicits cell-mediated immunity but does not affect disease progression in HIV-1-infected male subjects: results from a randomized placebo-controlled trial (the Step Study). J. Infect. Dis. 203, 765\u2013772 (2011).","journal-title":"J. Infect. Dis."},{"key":"BFnri3694_CR94","unstructured":"UNAIDS. Factsheet. [online], (2013)."},{"key":"BFnri3694_CR95","doi-asserted-by":"crossref","unstructured":"The rgp120 HIV Vaccine Study Group. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J. Infect. Dis. 191, 654\u2013665 (2005).","DOI":"10.1086\/428404"},{"key":"BFnri3694_CR96","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1086\/508748","volume":"194","author":"P Pitisuttithum","year":"2006","unstructured":"Pitisuttithum, P. et al. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J. Infect. Dis. 194, 1661\u20131671 (2006).","journal-title":"J. Infect. Dis."},{"key":"BFnri3694_CR97","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1016\/S0140-6736(08)61591-3","volume":"372","author":"SP Buchbinder","year":"2008","unstructured":"Buchbinder, S. P. et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372, 1881\u20131893 (2008).","journal-title":"Lancet"},{"key":"BFnri3694_CR98","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa0908492","volume":"361","author":"S Rerks-Ngarm","year":"2009","unstructured":"Rerks-Ngarm, S. et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361, 2209\u20132220 (2009).","journal-title":"N. Engl. J. Med."},{"key":"BFnri3694_CR99","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/nature12744","volume":"503","author":"DH Barouch","year":"2013","unstructured":"Barouch, D. H. et al. Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature 503, 224\u2013228 (2013).","journal-title":"Nature"},{"key":"BFnri3694_CR100","unstructured":"World Health Organization. Global tuberculosis report 2013. (WHO, 2013)."},{"key":"BFnri3694_CR101","unstructured":"AERAS. Crucell Ad35\/MVA85A. [online], (2014)."},{"key":"BFnri3694_CR102","unstructured":"World Health Organization. World Malaria Day, 25 April 2014. Invest in the future. Defeat malaria. [online], (2014)."},{"key":"BFnri3694_CR103","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1126\/science.1241800","volume":"341","author":"RA Seder","year":"2013","unstructured":"Seder, R. A. et al. Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science 341, 1359\u20131365 (2013).","journal-title":"Science"},{"key":"BFnri3694_CR104","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/nature10124","volume":"473","author":"R Rappuoli","year":"2011","unstructured":"Rappuoli, R. & Aderem, A. A 2020 vision for vaccines against HIV, tuberculosis and malaria. Nature 473, 463\u2013469 (2011).","journal-title":"Nature"},{"key":"BFnri3694_CR105","doi-asserted-by":"publisher","first-page":"10501","DOI":"10.1073\/pnas.0804699105","volume":"105","author":"F Mosca","year":"2008","unstructured":"Mosca, F. et al. Molecular and cellular signatures of human vaccine adjuvants. Proc. Natl Acad. Sci. USA 105, 10501\u201310506 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnri3694_CR106","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/ni.1688","volume":"10","author":"TD Querec","year":"2009","unstructured":"Querec, T. D. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nature Immunol. 10, 116\u2013125 (2009).","journal-title":"Nature Immunol."},{"key":"BFnri3694_CR107","doi-asserted-by":"publisher","first-page":"3119","DOI":"10.1084\/jem.20082292","volume":"205","author":"D Gaucher","year":"2008","unstructured":"Gaucher, D. et al. Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses. J. Exp. Med. 205, 3119\u20133131 (2008).","journal-title":"J. Exp. Med."},{"key":"BFnri3694_CR108","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1126\/science.1246829","volume":"343","author":"R Ravindran","year":"2014","unstructured":"Ravindran, R. et al. Vaccine activation of the nutrient sensor GCN2 in dendritic cells enhances antigen presentation. Science 343, 313\u2013317 (2014).","journal-title":"Science"},{"key":"BFnri3694_CR109","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/ni.2789","volume":"15","author":"S Li","year":"2014","unstructured":"Li, S. et al. Molecular signatures of antibody responses derived froma systems biology study of five human vaccines. Nature Immunol. 15, 195\u2013204 (2014).","journal-title":"Nature Immunol."},{"key":"BFnri3694_CR110","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.cell.2014.03.031","volume":"157","author":"JS Tsang","year":"2014","unstructured":"Tsang, J. S. et al. Global analyses of human immune variation reveal baseline predictors of postvaccination. Cell 157, 499\u2013513 (2014).","journal-title":"Cell"},{"key":"BFnri3694_CR111","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1126\/science.1221466","volume":"336","author":"R Rappuoli","year":"2012","unstructured":"Rappuoli, R. & Dormitzer, P. R. Influenza: options to improve pandemic preparation. Science 336, 1531\u20131533 (2012).","journal-title":"Science"},{"key":"BFnri3694_CR112","unstructured":"Centers for Disease Control and Prevention. Updated CDC Estimates of 2009 H1N1 Influenza Cases, Hospitalizations and Deaths in the United States, April 2009 \u2013 April 10, 2010. [online], (2010)."},{"key":"BFnri3694_CR113","unstructured":"Centers for Disease Control and Prevention. FluView. A weekly influenza surveillance report prepared by the Influenza Division. [online]"}],"container-title":["Nature Reviews Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/nri3694.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/nri3694","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/nri3694.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T23:34:04Z","timestamp":1733960044000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nri3694"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6,13]]},"references-count":113,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["BFnri3694"],"URL":"https:\/\/doi.org\/10.1038\/nri3694","relation":{},"ISSN":["1474-1733","1474-1741"],"issn-type":[{"value":"1474-1733","type":"print"},{"value":"1474-1741","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6,13]]},"assertion":[{"value":"13 June 2014","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ennio De Gregorio and Rino Rappuoli are full-time employees and shareholders of Novartis Vaccines. The following products are commercialized by Novartis or are in the pipeline of Novartis Vaccines: MF59 adjuvant; TLR7-based adjuvants; vaccines against <i>Haemophilus influenzae<\/i>, meningococcus serogroups B, C and ACYW, influenza virus, pertussis, respiratory syncytial virus, and group A and group B streptococcus; and RNA vaccines based on self-amplifying mRNA (SAM).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}